Depression Drug Market to Reach a Valuation of US$ 5000 Mn by 2026
Depression Drugs Market – Snapshot
Depression is an indication when one feels down in the dumps, miserable, unhappy, blue, or sad. It is natural for people to feel this way for a short duration of time, sometime in life. However, clinical depression is a condition when a person feels frustrated, angry, lost, or sad on a daily basis, for a long duration of time. In 2017, depression drugs were valued at approximately US$ 6,500 Mn and are anticipated to register a CAGR of over -2% from 2018 to 2026 to reach value of approximately over US$ 5000 Mn by 2026.
Increasing prevalence of major depression disorder drives the expansion of the market from 2018 to 2026. According to the National Institute of Mental Health, approximately 10.3 million adults in the U.S. had at least one major depressive episode with severe impairment in 2016. The number represented 4.3% of all adults in the U.S. Higher prevalence of depression was observed among female adults, which accounted for approximately 8.5% as against 4.8% among male adults. The highest prevalence of major depression disorder was observed among the people of 18 to 25 years of age, which accounted for 10.9% of all adults in the U.S affected by at least one major depressive episode with severe impairment in 2016. According to the American Psychiatric Association, approximately 14.8 million adults in the U.S. are affected by depression.
Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1151
The global depression drugs market can be been classified on the basis of distribution channel, disease type, drug class, and region. Based on drug class, the market can be categorized into atypical antipsychotics, serotonin–norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, central nervous system (CNS) stimulant, and others. Among these, the atypical antipsychotics segment leads the market and is expected to continue its dominance during the forecast period, followed by the Serotonin–Norepinephrine Reuptake Inhibitor segment. The significant market share of the atypical antipsychotics segment can be attributed to the launch of drugs in developed countries, such as the U.S. and Canada.
In terms of disease type, the depression drugs market can be been classified into major depressive disorder, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others. Major depression disorder accounted for highest market share in 2017 owing to high work stress all over the world.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1151
Based on distribution channel, the depression drugs market can be bifurcated into online pharmacies, hospital pharmacies, and retail pharmacies. Among these, the retail pharmacies segment held the maximum share of the market in 2017. The segment is projected to dominate the market during the forecast period, which can be attributed to the increasing prevalence of depression disorders across the world and rising preference of patients to buy drugs from retail pharmacies. However, hospital pharmacies and retail pharmacies are anticipated to witness a decline in their market share during the forecast period owing to expiry of exclusivity of depression drugs.
Geographically, North America constituted the leading share of the global depression drugs market in 2017. North America being the home company of many key players of the global depression drugs market is likely responsible for the dominance of market share of the region. Europe accounted for the second leading share of the global depression drugs market in 2017, which can be ascribed to the increase in research and development activities on depression drugs in the region. The depression drugs market in Middle East & Africa is anticipated to grow at a significant rate during the forecast period. Increase in government initiatives in the health care sector in the developing countries of the region is projected to fuel the growth of the depression drugs market in the region. Initiatives by the local government to attain self-sufficiency in the manufacturing of depression drugs is likely to boost the depression drugs market in Asia Pacific and Latin America.
Major companies operating in the global depression drugs and profiled in the report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company Ltd, Sebela Pharmaceutical Inc, and Johnson & Johnson. These players have adopted both inorganic and organic growth strategies to expand their drug offerings, strengthen their reach globally, garner market share, and increase their customer base.
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/